Feldman and Schor explain that the patent dance is a complex process to determine which of a biologic manufacturer’s patents ...

From the creation of a regulatory pathway for biosimilars in the EU only three biologics experienced EU biosimilar competition until the launch of Remsima/Inflectra in 2013, and none have (as at ...

Research indicates that high-yield stock portfolios outperform over time. Does your portfolio have the right mix of ...

There were also five new drugs referencing the ophthalmology drug Eylea (aflibercept) that gained FDA approval in 2024.

Yescarta is a biologic drug, which means it’s made from parts of living organisms. It doesn’t come in a biosimilar form. Biosimilars are like generic drugs, but unlike generics (which are made ...

Autoimmune Disease Therapeutics Market projected for significant growth from 2025 to 2035, driven by biologics, innovation, and rising prevalence Global demand for autoimmune disease therapeutics is ...

Under the Medicare Drug Price Negotiation Program, the HHS secretary negotiates directly with manufacturers on the prices ...

Looking further ahead, NHS England envisages savings as a whole from biosimilars of some £400 - £500 million per year by 2021, if it can increase uptake of ‘best value biologic medicines’.

As healthcare systems worldwide shift toward personalized treatment, biopharmaceuticals are gaining momentum for their ability to target disease mechanisms at the molecular level. The rapid ...

In the past month, President Trump signed two executive orders concerning drug access and affordability, including for biologics and biosimilar ... 13 directives related to that policy, with ...

FDA Commissioner Marty Makary announced Thursday that the agency will soon provide clear guidelines to vaccine manufacturers ...

MANCHESTER, England — The risks for infection are broadly similar regardless of the biologic or targeted synthetic disease-modifying drug used to treat inflammatory arthritis, but different ...